Bloomlife, Inc.

Based in the US, Bloomlife, Inc. provides innovative FDA-cleared monitoring devices for high-risk pregnancies, enhancing maternal care through technology-driven solutions designed for expectant mothers' health management. Bloomlife, Inc. specializes in connected devices for maternal health, founded in 2014 in San Francisco, US by Eric Dy, Julien Penders, and Thad Tayo.

The company has secured a total of USD 12. 929 mn in funding through 4 deals, with its latest funding round being a Series B that raised USD 12. 929 mn from investors including 15th Rock, Grove Foundation, Kapor Capital, LeanSquare, Noshaq, RH Capital, and Stardust Equity, bringing its current valuation to USD 22. 586 mn.

Bloomlife Connect offers a suite of FDA-cleared, cellular-enabled connected devices designed primarily for high-risk pregnant women who require enhanced monitoring and clinical management. Once prescribed by OB/GYNs through electronic medical records, these devices are shipped directly to patients' homes, enabling comprehensive education and onboarding. The core functionality includes daily reminders, automatic data transmission to healthcare providers, and real-time feedback, aiming to alleviate stress and empower expectant mothers during their pregnancy. Bloomlife's revenue model is centered around B2B partnerships with healthcare providers who integrate Bloomlife Connect devices into their maternal care protocols.

Revenue is generated as healthcare providers enroll patients in the program and the associated Bloomlife Connect devices are billed accordingly, with transactions potentially structured through subscription services or direct sales agreements. This model supports continuous patient care while improving the quality of maternal care delivered by healthcare practices. Bloomlife, Inc. plans to leverage its recent funding from Rhia Ventures to further develop its product offerings and enhance its market presence.

The company is exploring new product designs for launch aimed at expanding its suite of connected devices for high-risk pregnancies. Additionally, Bloomlife intends to enter European markets to broaden its reach by the end of 2024, utilizing insights from its existing B2B partnerships to inform its strategies.